Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

A theory for polymicrogyria and brain arteriovenous malformations in HHT.

Klostranec JM, Chen L, Mathur S, McDonald J, Faughnan ME, Ratjen F, Krings T.

Neurology. 2019 Jan 1;92(1):34-42. doi: 10.1212/WNL.0000000000006686.

PMID:
30584075
2.

Decreased Levels of MicroRNAs-28-5p, -361-3p and Increased Insulin-Like Growth Factor 1 mRNA Levels in Mononuclear Cells from Hereditary Hemorrhagic Telangiectasia Patients.

Cannavicci A, Zhang Q, Dai SC, Faughnan ME, Kutryk M.

Can J Physiol Pharmacol. 2018 Dec 4. doi: 10.1139/cjpp-2018-0508. [Epub ahead of print]

PMID:
30512964
3.

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.

Faughnan ME, Gossage JR, Chakinala MM, Oh SP, Kasthuri R, Hughes CCW, McWilliams JP, Parambil JG, Vozoris N, Donaldson J, Paul G, Berry P, Sprecher DL.

Angiogenesis. 2019 Feb;22(1):145-155. doi: 10.1007/s10456-018-9646-1. Epub 2018 Sep 6.

PMID:
30191360
4.

Association of common candidate variants with vascular malformations and intracranial hemorrhage in hereditary hemorrhagic telangiectasia.

Pawlikowska L, Nelson J, Guo DE, McCulloch CE, Lawton MT, Kim H, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group.

Mol Genet Genomic Med. 2018 May;6(3):350-356. doi: 10.1002/mgg3.377. Epub 2018 Mar 6.

5.

Systematic screening in hereditary hemorrhagic telangiectasia: a review.

Kroon S, Snijder RJ, Faughnan ME, Mager HJ.

Curr Opin Pulm Med. 2018 May;24(3):260-268. doi: 10.1097/MCP.0000000000000472. Review.

PMID:
29470256
6.

Human-centred design in global health: A scoping review of applications and contexts.

Bazzano AN, Martin J, Hicks E, Faughnan M, Murphy L.

PLoS One. 2017 Nov 1;12(11):e0186744. doi: 10.1371/journal.pone.0186744. eCollection 2017. Review.

7.

Surgical Treatment vs Nonsurgical Treatment for Brain Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia: A Retrospective Multicenter Consortium Study.

Meybodi AT, Kim H, Nelson J, Hetts SW, Krings T, terBrugge KG, Faughnan ME, Lawton MT; Brain Vascular Malformation Consortium HHT Investigator Group.

Neurosurgery. 2018 Jan 1;82(1):35-47. doi: 10.1093/neuros/nyx168.

8.

Antithrombotic Use Predicts Recanalization of Embolized Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.

Martin JL, Faughnan ME, Prabhudesai V.

Can Assoc Radiol J. 2017 Nov;68(4):463-467. doi: 10.1016/j.carj.2017.05.001. Epub 2017 Sep 15. No abstract available.

PMID:
28927739
9.

SMAD4 gene mutation increases the risk of aortic dilation in patients with hereditary haemorrhagic telangiectasia.

Vorselaars VMM, Diederik A, Prabhudesai V, Velthuis S, Vos JA, Snijder RJ, Westermann CJJ, Mulder BJ, Ploos van Amstel JK, Mager JJ, Faughnan ME, Post MC.

Int J Cardiol. 2017 Oct 15;245:114-118. doi: 10.1016/j.ijcard.2017.06.059.

PMID:
28874282
10.

Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia.

Kasthuri RS, Montifar M, Nelson J, Kim H, Lawton MT, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group.

Am J Hematol. 2017 Jun 22. doi: 10.1002/ajh.24832. [Epub ahead of print] No abstract available.

11.

Alternative designs for clinical trials in rare diseases.

Abrahamyan L, Feldman BM, Tomlinson G, Faughnan ME, Johnson SR, Diamond IR, Gupta S.

Am J Med Genet C Semin Med Genet. 2016 Dec;172(4):313-331. doi: 10.1002/ajmg.c.31533. Epub 2016 Nov 14. Review.

PMID:
27862920
12.

Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.

Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR.

JAMA. 2016 Sep 6;316(9):943-51. doi: 10.1001/jama.2016.11724.

PMID:
27599329
13.

Persistent infiltration and pro-inflammatory differentiation of monocytes cause unresolved inflammation in brain arteriovenous malformation.

Zhang R, Han Z, Degos V, Shen F, Choi EJ, Sun Z, Kang S, Wong M, Zhu W, Zhan L, Arthur HM, Oh SP, Faughnan ME, Su H.

Angiogenesis. 2016 Oct;19(4):451-461. doi: 10.1007/s10456-016-9519-4. Epub 2016 Jun 20.

14.

Life expextancy of parents with Hereditary Haemorrhagic Telangiectasia.

de Gussem EM, Edwards CP, Hosman AE, Westermann CJ, Snijder RJ, Faughnan ME, Mager JJ.

Orphanet J Rare Dis. 2016 Apr 22;11:46. doi: 10.1186/s13023-016-0427-x.

15.

Pulmonary arteriovenous malformation (PAVM) reperfusion after percutaneous embolization: Sensitivity and specificity of non-enhanced CT.

Bélanger C, Chartrand-Lefebvre C, Soulez G, Faughnan ME, Tahir MR, Giroux MF, Gilbert P, Perreault P, Bouchard L, Oliva VL, Therasse E.

Eur J Radiol. 2016 Jan;85(1):150-157. doi: 10.1016/j.ejrad.2015.11.014. Epub 2015 Nov 10.

PMID:
26724660
16.

Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation.

Singer LG, Chowdhury NA, Faughnan ME, Granton J, Keshavjee S, Marras TK, Tullis DE, Waddell TK, Tomlinson G.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):965-73. doi: 10.1164/rccm.201501-0126OC.

PMID:
26131729
17.

Prevalence and nature of dyspnea in patients with hereditary hemorrhagic telangiectasia (HHT).

Rozenberg D, Leek E, Faughnan ME.

Respir Med. 2015 Jun;109(6):768-77. doi: 10.1016/j.rmed.2015.04.003. Epub 2015 Apr 15.

18.

Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia.

Kim H, Nelson J, Krings T, terBrugge KG, McCulloch CE, Lawton MT, Young WL, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group.

Stroke. 2015 May;46(5):1362-4. doi: 10.1161/STROKEAHA.114.007367. Epub 2015 Apr 9.

19.

The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.

Pawlikowska L, Nelson J, Guo DE, McCulloch CE, Lawton MT, Young WL, Kim H, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group.

Am J Med Genet A. 2015 Jun;167(6):1262-7. doi: 10.1002/ajmg.a.36936. Epub 2015 Apr 2.

20.

Neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations.

Krings T, Kim H, Power S, Nelson J, Faughnan ME, Young WL, terBrugge KG; Brain Vascular Malformation Consortium HHT Investigator Group.

AJNR Am J Neuroradiol. 2015 May;36(5):863-70. doi: 10.3174/ajnr.A4210. Epub 2015 Jan 8.

21.

The Inferior Alveolar Nerve of the Horse: Course and Anatomical Relationship with Mandibular Cheek Teeth.

Iacopetti I, Faughnan M, Bono S, Cozzi B, Facchini C.

Anat Histol Embryol. 2015 Oct;44(5):333-7. doi: 10.1111/ahe.12144. Epub 2014 Sep 3.

PMID:
25182080
22.

Histogram flow mapping with optical coherence tomography for in vivo skin angiography of hereditary hemorrhagic telangiectasia.

Cheng KH, Mariampillai A, Lee KK, Vuong B, Luk TW, Ramjist J, Curtis A, Jakubovic H, Kertes P, Letarte M, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group, Yang VX.

J Biomed Opt. 2014 Aug;19(8):086015. doi: 10.1117/1.JBO.19.8.086015.

23.

The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey.

Zaffar N, Ravichakaravarthy T, Faughnan ME, Shehata N.

Ann Hematol. 2015 Jan;94(1):145-52. doi: 10.1007/s00277-014-2169-y. Epub 2014 Jul 27.

PMID:
25064693
24.

Targeting under-diagnosis in hereditary hemorrhagic telangiectasia: a model approach for rare diseases?

Latino GA, Brown D, Glazier RH, Weyman JT, Faughnan ME.

Orphanet J Rare Dis. 2014 Jul 25;9:115. doi: 10.1186/s13023-014-0115-7.

25.

Circulating angiogenic cell dysfunction in patients with hereditary hemorrhagic telangiectasia.

Zucco L, Zhang Q, Kuliszewski MA, Kandic I, Faughnan ME, Stewart DJ, Kutryk MJ.

PLoS One. 2014 Feb 25;9(2):e89927. doi: 10.1371/journal.pone.0089927. eCollection 2014.

26.

Outcomes of pregnancy in women with hereditary hemorrhagic telangiectasia.

de Gussem EM, Lausman AY, Beder AJ, Edwards CP, Blanker MH, Terbrugge KG, Mager JJ, Faughnan ME.

Obstet Gynecol. 2014 Mar;123(3):514-20. doi: 10.1097/AOG.0000000000000120.

PMID:
24499751
27.

Severity score for hereditary hemorrhagic telangiectasia.

Latino GA, Kim H, Nelson J, Pawlikowska L, Young W, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group.

Orphanet J Rare Dis. 2014 Dec 29;9:188. doi: 10.1186/s13023-014-0188-3.

28.

Cumulative radiation dose in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations.

Hanneman K, Faughnan ME, Prabhudesai V.

Can Assoc Radiol J. 2014 May;65(2):135-40. doi: 10.1016/j.carj.2013.02.007. Epub 2013 Aug 6.

29.

Prognostic relevance of dynamic hyperinflation during cardiopulmonary exercise testing in adult patients with cystic fibrosis.

Stevens D, Stephenson A, Faughnan ME, Leek E, Tullis E.

J Cyst Fibros. 2013 Dec;12(6):655-61. doi: 10.1016/j.jcf.2013.04.010. Epub 2013 May 23.

30.

The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia.

Grosse SD, Boulet SL, Grant AM, Hulihan MM, Faughnan ME.

Genet Med. 2014 Jan;16(1):33-9. doi: 10.1038/gim.2013.66. Epub 2013 May 23.

31.

Brain Vascular Malformation Consortium: Overview, Progress and Future Directions.

Akers AL, Ball KL, Clancy M, Comi AM, Faughnan ME, Gopal-Srivastava R, Jacobs TP, Kim H, Krischer J, Marchuk DA, McCulloch CE, Morrison L, Moses M, Moy CS, Pawlikowska L, Young WL.

J Rare Disord. 2013 Apr 1;1(1):5.

32.

Prevalence of pulmonary arteriovenous malformations in children versus adults with hereditary hemorrhagic telangiectasia.

Latino GA, Al-Saleh S, Alharbi N, Edwards C, Faughnan ME, Ratjen F.

J Pediatr. 2013 Jul;163(1):282-4. doi: 10.1016/j.jpeds.2013.02.021. Epub 2013 Mar 20.

PMID:
23522378
33.

Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab.

Vlachou PA, Colak E, Koculym A, Kirpalani A, Kim TK, Hirschfield GM, Faughnan ME.

J Hepatol. 2013 Jul;59(1):186-9. doi: 10.1016/j.jhep.2013.02.006. Epub 2013 Feb 21.

34.

Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation.

Edwards CP, Shehata N, Faughnan ME.

Ann Hematol. 2012 Dec;91(12):1959-68. doi: 10.1007/s00277-012-1553-8. Epub 2012 Sep 30.

PMID:
23053175
35.

Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker.

Zhang Q, Kandic I, Faughnan ME, Kutryk MJ.

Biomarkers. 2013 Feb;18(1):23-9. doi: 10.3109/1354750X.2012.728624. Epub 2012 Oct 10.

PMID:
23051042
36.

Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: gene-phenotype correlations.

Nishida T, Faughnan ME, Krings T, Chakinala M, Gossage JR, Young WL, Kim H, Pourmohamad T, Henderson KJ, Schrum SD, James M, Quinnine N, Bharatha A, Terbrugge KG, White RI Jr.

Am J Med Genet A. 2012 Nov;158A(11):2829-34. doi: 10.1002/ajmg.a.35622. Epub 2012 Sep 18.

37.

Metabolic alkalosis in adults with stable cystic fibrosis.

Al-Ghimlas F, Faughnan ME, Tullis E.

Open Respir Med J. 2012;6:59-62. doi: 10.2174/1874306401206010059. Epub 2012 Jul 25.

38.

Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation.

Schwenter F, Faughnan ME, Gradinger AB, Berk T, Gryfe R, Pollett A, Cohen Z, Gallinger S, Durno C.

J Gastroenterol. 2012 Jul;47(7):795-804. doi: 10.1007/s00535-012-0545-8. Epub 2012 Feb 14.

PMID:
22331366
39.

Utility of contrast echocardiography for pulmonary arteriovenous malformation screening in pediatric hereditary hemorrhagic telangiectasia.

Al-Saleh S, Dragulescu A, Manson D, Golding F, Traubici J, Mei-Zahav M, Maclusky IB, Faughnan ME, Carpenter S, Ratjen F.

J Pediatr. 2012 Jun;160(6):1039-43.e1. doi: 10.1016/j.jpeds.2011.11.038. Epub 2011 Dec 21.

PMID:
22196589
40.

Rare lung disease research: strategies for improving identification and recruitment of research participants.

Gupta S, Bayoumi AM, Faughnan ME.

Chest. 2011 Nov;140(5):1123-1129. doi: 10.1378/chest.11-1094.

PMID:
22045877
41.

Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment.

Bharatha A, Faughnan ME, Kim H, Pourmohamad T, Krings T, Bayrak-Toydemir P, Pawlikowska L, McCulloch CE, Lawton MT, Dowd CF, Young WL, Terbrugge KG.

Stroke. 2012 Jan;43(1):72-8. doi: 10.1161/STROKEAHA.111.629865. Epub 2011 Oct 27.

42.

BODE index and quality of life in advanced chronic obstructive pulmonary disease before and after lung transplantation.

Eskander A, Waddell TK, Faughnan ME, Chowdhury N, Singer LG.

J Heart Lung Transplant. 2011 Dec;30(12):1334-41. doi: 10.1016/j.healun.2011.06.006. Epub 2011 Jul 22.

PMID:
21782467
43.

Juvenile polyposis syndrome, SMAD4 mutations, and hereditary hemorrhagic telangiectasia.

Schwenter F, Ratjen F, Berk T, Gallinger S, Gryfe R, Gradinger AB, Faughnan ME, Durno CA.

J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):120-2. doi: 10.1097/MPG.0b013e3182238514. No abstract available.

PMID:
21572342
44.

Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasia.

Al-Saleh S, John PR, Letarte M, Faughnan ME, Belik J, Ratjen F.

Pediatrics. 2011 Jun;127(6):e1615-20. doi: 10.1542/peds.2010-2366. Epub 2011 May 2.

45.

A framework for applying unfamiliar trial designs in studies of rare diseases.

Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM.

J Clin Epidemiol. 2011 Oct;64(10):1085-94. doi: 10.1016/j.jclinepi.2010.12.019. Epub 2011 May 6. Review.

PMID:
21530171
46.

Idiopathic pulmonary arteriovenous malformations: clinical and imaging characteristics.

Wong HH, Chan RP, Klatt R, Faughnan ME.

Eur Respir J. 2011 Aug;38(2):368-75. doi: 10.1183/09031936.00075110. Epub 2010 Dec 22.

47.

Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.

Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM.

Clin Gastroenterol Hepatol. 2010 Dec;8(12):1095-8. doi: 10.1016/j.cgh.2010.08.011. Epub 2010 Nov 9.

PMID:
20816858
48.

Lobar embolization for treatment of diffuse pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a case report.

Wei CW, Faughnan ME, Menard A, Frenklah Y, Saposnik G, Prabhudesai V.

J Vasc Interv Radiol. 2010 Jul;21(7):1105-8. doi: 10.1016/j.jvir.2010.02.040. Epub 2010 May 26.

PMID:
20537912
49.

Embolization of pulmonary arteriovenous malformations with amplatzer vascular plugs: safety and midterm effectiveness.

Letourneau-Guillon L, Faughnan ME, Soulez G, Giroux MF, Oliva VL, Boucher LM, Dubois J, Prabhudesai V, Therasse E.

J Vasc Interv Radiol. 2010 May;21(5):649-56. doi: 10.1016/j.jvir.2010.01.026. Epub 2010 Mar 25.

PMID:
20346701
50.

Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.

Gallione C, Aylsworth AS, Beis J, Berk T, Bernhardt B, Clark RD, Clericuzio C, Danesino C, Drautz J, Fahl J, Fan Z, Faughnan ME, Ganguly A, Garvie J, Henderson K, Kini U, Leedom T, Ludman M, Lux A, Maisenbacher M, Mazzucco S, Olivieri C, Ploos van Amstel JK, Prigoda-Lee N, Pyeritz RE, Reardon W, Vandezande K, Waldman JD, White RI Jr, Williams CA, Marchuk DA.

Am J Med Genet A. 2010 Feb;152A(2):333-9. doi: 10.1002/ajmg.a.33206.

PMID:
20101697

Supplemental Content

Loading ...
Support Center